Seaport Therapeutics (SPTX)
Develops lymphatic-targeted oral prodrugs for neuropsychiatric disorders.
Something off on this page? Send us feedback.
Develops lymphatic-targeted oral prodrugs for depression, anxiety, and related neuropsychiatric disorders. Its Glyph platform modifies known molecules to bypass first-pass liver metabolism, while the business remains a financed clinical-development operation with no approved products or revenue.
Invents oral prodrugs for depression, anxiety, and related neuropsychiatric disorders through its Glyph platform. The platform attaches a cleavable, lipid-like structure to known molecules to route absorption through intestinal lymph rather than the liver, aiming to change oral exposure, liver exposure, and metabolism-driven tolerability while creating patentable prodrug compositions.
Its named pipeline includes GlyphAllo for major depressive disorder, GlyphAgo for generalized anxiety disorder, and Glyph2BLSD for depressive, post-traumatic stress, and headache disorders. Research is based in Boston, with early clinical work in Australia and an ongoing lead study recruiting in the United States and Europe. Clinical and commercial-scale manufacturing and substantial development work are outsourced to contract manufacturers, CROs, and other vendors; no product is approved or commercialized.
Company facts
Unavailable right now.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $273.3M · Total debt $5.0M · Total assets $441.7M · Shareholders' equity $422.6M
- Revenue
- $0
- Operating income
- −$65.8M
- Net income
- −$62.6M
No dividends on record.
| Institutions55 holders · as of Jun 30, 2026 | 70.07% | 37.51M shares | |
| Otherremainder | 29.93% | 16.02M shares |
53.53M company shares as of Aug 21, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Arch Venture Management, LLCInstitution | 11.76% | 6.29M | 13Fas of Jun 30, 2026 |
General Atlantic, L.P.Institution | 11.40% | 6.10M | 13Fas of Jun 30, 2026 |
Sofinnova Investments, Inc.Institution | 6.66% | 3.56M | 13Fas of Jun 30, 2026 |
Goldman Sachs Group IncInstitution | 4.07% | 2.18M | 13Fas of Jun 30, 2026 |
TRV GP Vi, LLCInstitution | 3.85% | 2.06M | 13Fas of Jun 30, 2026 |
| See all 25 → | |||
13F — a manager's quarterly holdings
Insider tradesForm 4
Nothing filed in the last 12 months.
- Johnson & Johnson
Marketed MDD and treatment-resistant depression therapies.
- AbbVie
Vraylar and bretisilocin span marketed and pipeline MDD.
- Axsome Therapeutics
Marketed oral MDD therapy with a growing sales and payer base.
- Definium Therapeutics
Late-stage lysergide program in GAD, MDD, and neuroplasticity.
- Xenon Pharmaceuticals
Phase 3 oral azetukalner program in major depressive disorder.
- Viatris
Marketed GAD options, including Effexor SR, compete for access.
- Helus Pharma
Phase 3 MDD and Phase 2 GAD serotonergic agonist programs.
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Seaport Therapeutics | $24.88 | +5.38% | $1.33B | — | — | — | — |
| Johnson & Johnson | $275.50 | +0.09% | $663.23B | 31.9 | 23.1 | 6.8 | +6.6% |
| AbbVie | $262.35 | +0.24% | $462.37B | 73.7 | 17.2 | 7.2 | +10.2% |
| Axsome Therapeutics | $212.18 | +1.08% | $10.80B | — | 1,800.7 | 13.9 | +44.2% |
| Definium Therapeutics | $38.87 | −0.15% | $5.16B | — | — | — | — |
| Xenon Pharmaceuticals | $60.60 | +0.60% | $5.82B | — | — | — | — |
| Viatris | $16.99 | −0.61% | $19.90B | — | 6.7 | 1.4 | +4.9% |
| Helus Pharma | $12.09 | +1.21% | $740.7M | — | — | — | — |
| Median | 52.8 | 20.2 | 7.0 | +8.4% |